^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Colorectal Cancer

    Related cancers:
    1d
    Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers (clinicaltrials.gov)
    P1, N=162, Recruiting, Novartis Pharmaceuticals | N=124 --> 162 | Trial completion date: Jun 2030 --> Jan 2031 | Trial primary completion date: Jun 2030 --> Jan 2031
    Enrollment change • Trial completion date • Trial primary completion date
    1d
    COLUMBIA 1: COLUMBIA-1: Novel Oncology Therapies in Combination With Chemotherapy and Bevacizumab as First- Line Therapy in MSS-CRC (clinicaltrials.gov)
    P1/2, N=61, Active, not recruiting, MedImmune LLC | Trial completion date: Nov 2025 --> Nov 2026
    Trial completion date
    |
    Avastin (bevacizumab) • Imfinzi (durvalumab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • oleclumab (MEDI9447)
    1d
    A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=405, Recruiting, Lepu Biopharma Co., Ltd. | Phase classification: P1/2 --> P1
    Phase classification
    1d
    Intravital Microscopy in Human Solid Tumors (clinicaltrials.gov)
    P=N/A, N=85, Recruiting, Mayo Clinic | Trial completion date: May 2026 --> Sep 2026 | Trial primary completion date: May 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    1d
    Clinical Study of Acupoint Application on Relieving qi Deficiency and Constipation in Patients Undergoing Chemotherapy (clinicaltrials.gov)
    P=N/A, N=106, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University
    New trial
    1d
    Colonic: Initial Safety of SFM Plus OTOLoc for Creating Side-to-side or End-to-side Colorectal Anastomoses (clinicaltrials.gov)
    P=N/A, N=20, Not yet recruiting, GI Windows, Inc.
    New trial
    1d
    A Multi-PTM omics atlas uncovers novel aging regulators in colorectal cancer. (PubMed, BMC Cancer)
    This study presents the first integrative network map of aging regulation in CRC based on multiple PTMs. Notably, hub proteins such as LMNB1 have emerged as key regulatory targets. These findings provide a theoretical foundation for the development of aging-cancer axis-related biomarkers and therapeutic strategies for CRC.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • MAPK1 (Mitogen-activated protein kinase 1) • CDK1 (Cyclin-dependent kinase 1) • SOD2 (Superoxide Dismutase 2)
    1d
    CXCR3 gene as a therapeutic target in colorectal cancer. (PubMed, BMC Cancer)
    Our findings suggest that downregulation of CXCR3 mRNA inhibits colorectal cancer cell growth through inhibition of the AKT‒mTOR pathway. The CXCR3 receptor can be considered a new therapeutic target in colorectal cancer therapy.
    Journal • IO biomarker
    |
    CXCR3 (C-X-C Motif Chemokine Receptor 3) • ANXA5 (Annexin A5)
    1d
    Urothelium marker UPK2 identifies aggressive colorectal cancers with distinct molecular and histological features. (PubMed, Br J Cancer)
    UPK2 marks a distinct subset of CRCs with poor prognosis, epithelial-mesenchymal transition, micropapillary growth, and squamous differentiation. These findings may affect the development of targeted therapies in precision medicine.
    Journal
    |
    TP53 (Tumor protein P53) • KRT17 (Keratin 17)
    |
    TP53 mutation
    1d
    Lypd6b depletion promotes CD8+ T cell-mediated anti-tumor immunity via metabolic reprogramming in colorectal cancer. (PubMed, Nat Commun)
    Notably, Lypd6b deficient CD8+ T cells have a more potent antitumor effect when combined with anti-PD1 antibody. Thus, Lypd6b as a negative regulator for T cell immunity promotes CRC development, providing a molecular target with therapeutic potential in CRC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    LDHA (Lactate dehydrogenase A) • CD8 (cluster of differentiation 8)
    1d
    Multi-omics integration deciphers immune-metabolic heterogeneity in CRC: A prognostic model and therapeutic strategies targeting ANGPTL4/FABP4/RBP7. (PubMed, Comput Biol Med)
    This multi-omics study integrates multi-omics data to elucidate the immune-metabolic heterogeneity in CRC, establishing a precise prognostic model and providing bioinformatic evidence for key roles of ANGPTL4, FABP4, and RBP7 in the tumor microenvironment, thereby suggesting novel strategies to overcome immunotherapy resistance.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • MIR21 (MicroRNA 21) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL22 (C-C Motif Chemokine Ligand 22) • CX3CL1 (C-X3-C Motif Chemokine Ligand 1) • NOS2 (Nitric Oxide Synthase 2) • ANGPTL4 (Angiopoietin Like 4) • FABP4 (Fatty Acid Binding Protein 4) • RBP7 (Retinol Binding Protein 7)
    |
    rosiglitazone
    1d
    NPR3 promotes colorectal cancer cell proliferation, migration, invasion, and chemotherapy resistance. (PubMed, Biochim Biophys Acta Gen Subj)
    The LNMRGS is a robust prognostic signature for CRC. NPR3 plays a key role in metastatic progression and chemoresistance, suggesting it as a potential therapeutic target.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • NPR3 (Natriuretic Peptide Receptor 3) • ITGB3 (Integrin Subunit Beta 3)
    |
    KRAS mutation
    |
    5-fluorouracil • oxaliplatin